Inovio's communications dept just emailed me this afternoon in response to my request for clarity on upcoming data and funding announcements (below). Reading between the lines, I would guess publication in Nejm, Nature, Lancet or Science more likely this week, defintely before earnings call, and a major funding not locked in but very likely. Since they plan to use external funding for ph2/3, I am guessing $1b or more before summer ends (mid-Sep) but likely late Aug.
"... We have a number of announcements to come in the coming weeks/months: We will reveal full results of our INO-4800 Ph. 1 trial in a major upcoming peer-reviewed journal. We also expect to begin a Phase 2/3 INO-4800 trial later this summer. In addition, we will announce INO-4800 animal challenge data. And we will announce our earnings on August 10.... I am not able to comment about potential funding. I can only reiterate that our goal is to continue the development of our COVID-19 vaccine using external funding like we’ve received from DoD, CEPI, and the Bill and Melinda Gates Foundation..."